We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+31.05%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$3.42B
AUM Growth
+$931M
Cap. Flow
+$320M
Cap. Flow %
9.36%
Top 10 Hldgs %
45.63%
Holding
88
New
10
Increased
35
Reduced
24
Closed
6

Top Buys

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$138M
2
BIIB icon
Biogen
BIIB
+$52.1M
3
CELG
Celgene Corp
CELG
+$46.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$37.1M
5
ALGN icon
Align Technology
ALGN
+$34.2M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$114M
2
CI icon
Cigna
CI
+$50M
3
MDT icon
Medtronic
MDT
+$38.2M
4
CVS icon
CVS Health
CVS
+$25.1M
5
NITE
Nightstar Therapeutics plc American Depositary Shares
NITE
+$20.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.09%
2 Financials 2.23%
3 Miscellaneous 1.67%
4 Energy 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBAY
26
DELISTED
Cymabay Therapeutics
CBAY
$39.1M 1.14%
2,943,765
-5,100
-0.2% -$54.2K
BIIB icon
27
Biogen
BIIB
$32.3B
$39.1M 1.14%
+165,300
New +$52.1M
SRRK icon
28
Scholar Rock
SRRK
$7.04B
$38.5M 1.13%
2,051,089
+289,682
+16% +$5.1M
JAZZ icon
29
Jazz Pharmaceuticals
JAZZ
$15.9B
$38.5M 1.13%
269,480
+132,800
+97% +$17.3M
DCPH
30
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$37.8M 1.11%
1,628,653
-24,527
-1% -$642K
ANAB icon
31
AnaptysBio
ANAB
$1.67B
$36.3M 1.06%
496,918
+132,868
+36% +$9.17M
IMGN
32
DELISTED
Immunogen Inc
IMGN
$35.4M 1.04%
13,063,767
+2,179,160
+20% +$9.44M
OXFD
33
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$34.5M 1.01%
2,001,467
-226,040
-10% -$3.58M
REPL icon
34
Replimune Group
REPL
$1.46B
$33.7M 0.99%
2,212,456
+23,499
+1% +$293K
UNH icon
35
UnitedHealth
UNH
$353B
$32.9M 0.96%
132,890
+17,390
+15% +$4.43M
NVTA
36
DELISTED
Invitae Corporation
NVTA
$32.2M 0.94%
1,374,175
+848,800
+162% +$15M
GRTS
37
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$31.3M 0.92%
2,353,735
+84,599
+4% +$1.13M
XERS icon
38
Xeris Biopharma Holdings
XERS
$1.55B
$30.1M 0.88%
3,000,641
+588,000
+24% +$7.53M
TCRR
39
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$28.7M 0.84%
+1,807,256
New +$32.1M
CBIO
40
Crescent Biopharma
CBIO
$659M
$25.1M 0.74%
20,182
+397
+2% +$455K
TDOC icon
41
Teladoc Health
TDOC
$1.18B
$24.5M 0.72%
439,900
+244,300
+125% +$14.9M
MOR
42
DELISTED
MorphoSys AG American Depositary Shares
MOR
$20.3M 0.59%
893,800
-1,800
-0.2% -$47.2K
EIDX
43
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$20M 0.58%
851,900
-1,600
-0.2% -$25.7K
HSKA
44
DELISTED
Heska Corp
HSKA
$19.2M 0.56%
226,013
+28,300
+14% +$2.55M
PRAH
45
DELISTED
PRA Health Sciences, Inc.
PRAH
$19.2M 0.56%
174,000
-20,800
-11% -$2.17M
TCDA
46
DELISTED
Tricida, Inc. Common Stock
TCDA
$18.9M 0.55%
490,300
-2,300
-0.5% -$53.6K
VAPO
47
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$18.9M 0.55%
126,415
-29,463
-19% -$4.23M
SYRS
48
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$15M 0.44%
164,520
-434
-0.3% -$30.2K
AXNX
49
DELISTED
Axonics, Inc. Common Stock
AXNX
$14.3M 0.42%
598,600
-1,400
-0.2% -$25.4K
ICUI icon
50
ICU Medical
ICUI
$4.38B
$12.4M 0.36%
51,721
-39,600
-43% -$9.5M
1
2
3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2019 Portfolio in Review

As of Q1 2019, Redmile Group held 88 positions worth $3.42B, up 37% from $2.49B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Redmile Group deployed $320M of net new capital in Q1 2019, opening 10 new positions and adding to 35 existing holdings. Its largest new stake was Biogen: 165,300 shares worth $39.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $114M trimmed.

  • Redmile Group's largest Q1 2019 buy was Biogen: 165,300 shares worth $39.1M.
  • Redmile Group added most to Amicus Therapeutics in Q1 2019, an estimated $138M increase.
  • Redmile Group's biggest Q1 2019 reduction was Array Biopharma Inc, cutting an estimated $114M.
  • Redmile Group fully exited Medtronic in Q1 2019, selling an estimated $38.2M.
  • Redmile Group's ten largest holdings make up 46% of its $3.42B portfolio in Q1 2019.
  • Redmile Group opened 10 new positions and closed 6 in Q1 2019.
  • Redmile Group's portfolio value rose 37% quarter-over-quarter to $3.42B.

Based on Redmile Group's 13F filing for Q1 2019, filed 15 May 2019.